Steatotic Liver Disease: Alcohol-Associated Liver Disease and Early Transplant

0:00Welcome to Board Pearls. This is episode two of two of the Steatotic Liver Disease chapter, in the Liver Disease module. This episode is alcohol-associated liver disease: the spectrum from steatosis to alcoholic hepatitis to cirrhosis, severe alcoholic hepatitis identified by the Maddrey function or MELD with prednisolone after infection is excluded, the day-seven Lille response decision, and early transplant for selected patients.

0:29Alcohol-associated liver disease is a single biology read across three histologic stages, where the drinker who walks in with simple steatosis at year five can return at year fifteen with cirrhosis, and most of the teaching is about the rate at which one stage transitions to the next. Nearly all heavy drinkers develop steatosis, a fraction progress to alcoholic steatohepatitis or fibrosis, and a smaller fraction of all patients with alcohol use disorder eventually develop cirrhosis, with the cirrhosis risk rising steeply with daily intake. Steatosis is fully reversible after a few weeks of abstinence, steatohepatitis clears in about half of patients who stop and progresses in a third, with that fraction climbing sharply if drinking continues, and once cirrhosis is established, decompensation and liver cancer both accrue at a few percent a year.

1:18The mechanism explains the lab pattern and several drug interactions. Ethanol is oxidized by alcohol dehydrogenase to acetaldehyde and then by aldehyde dehydrogenase to acetate, both steps consuming NAD and generating NADH, and the resulting shift in that ratio inhibits fatty-acid beta-oxidation, which is most of why alcohol drives steatosis. Acetaldehyde itself is toxic, forming protein adducts that act as neoantigens and recruit immune injury, and chronic drinking induces the microsomal ethanol-oxidizing enzyme, generating reactive oxygen species, which is also what makes the chronic drinker susceptible to acetaminophen toxicity at therapeutic doses, accelerates isoniazid injury, and worsens methotrexate fibrosis, while glutathione is depleted and gut-derived endotoxin translocates across an injured intestinal barrier to activate the liver macrophages, producing the neutrophil-rich inflammation with Mallory-Denk bodies and perivenular fibrosis that is the histologic signature. Risk modifiers explain why one drinker at a lower intake develops cirrhosis while another at a higher intake stays at steatosis: women carry higher injury risk at lower exposures because they have less body water and lower gastric enzyme activity and reach higher blood levels per drink, the same genetic variants that drive metabolic disease modify risk, coffee is protective, hepatitis C plus alcohol drives faster fibrosis than either alone, metabolic disease overlaps biologically which is why the intermediate category exists, and post-bariatric anatomy accelerates absorption and raises injury risk beyond what the drinking pattern predicts. Asian populations carry a loss-of-function variant in the second metabolic step, so carriers can't efficiently clear acetaldehyde and a single drink produces flushing and nausea, which makes most of them drink less so it's overall protective, but the carrier who drinks anyway despite the flush runs higher acetaldehyde exposure and higher upper-aerodigestive cancer risk and develops injury at exposures that wouldn't produce disease in non-carriers.

3:06The lab pattern outside the severe-hepatitis syndrome is recognizable: hepatomegaly with the AST greater than ALT, the ratio above one and a half and often above two, with both transaminases typically under four hundred, an elevated GGT and ferritin, and a blood count showing mild macrocytosis and thrombocytopenia. The AST-greater-than-ALT pattern has a mechanism, because alcohol is a mitochondrial toxin and AST has a mitochondrial isoform while ALT is cytoplasmic and depends on vitamin B6, which is depleted in chronic drinkers, lowering the measured ALT. And when transaminases exceed four hundred in a drinker, you should be thinking about something on top of alcohol, classically acetaminophen or ischemic hepatitis, because pure alcohol injury doesn't push the transaminases into the thousands.

3:55That sets up the acute syndrome sitting on top of underlying disease. Severe alcoholic hepatitis is the patient who develops rapid-onset jaundice in ongoing heavy drinking, often with fever, leukocytosis, hepatomegaly, and decompensation, with the lab pattern being the transaminase ceiling under four hundred with the same ratio, a bilirubin above three and often much higher, an elevated INR, and low albumin. The ninety-day mortality is thirty to forty percent, and that number is the urgency signal on every question the disease raises. The consensus criteria for probable alcoholic hepatitis have four components: jaundice with onset within the prior couple of months, heavy alcohol use for at least six months with fewer than sixty days of abstinence before onset, an AST between fifty and four hundred with the ratio over one and a half, and a total bilirubin over three, which lets you make the diagnosis without biopsy in the typical patient, with biopsy, increasingly transjugular because of the coagulopathy, reserved for atypical presentations. Severe disease is then defined by two prognostic anchors to know cold: the Maddrey discriminant function, computed from the prothrombin time and bilirubin, with a value above thirty-two defining severe disease, and the MELD score, which has largely replaced it because it's more reproducible and includes creatinine, with a value over twenty defining severe disease for treatment purposes, and MELD-Na is not used here.

5:21The trial that gives the modern treatment its shape randomized patients with severe disease to prednisolone, pentoxifylline, both, or placebo, and prednisolone produced a modest mortality reduction while pentoxifylline produced no benefit and was dropped from guidelines, and the trial also clarified the safety cost, because serious infections were roughly twice as common in prednisolone-treated patients, which is why every patient screened for steroids must first be screened for infection. So the treatment is prednisolone at forty milligrams daily for up to twenty-eight days, or intravenous methylprednisolone when oral isn't possible, with the contraindications being the careful part: uncontrolled infection, acute kidney injury with a creatinine above two and a half, and uncontrolled GI bleeding all defer or contraindicate steroids, as do active viral hepatitis, drug injury, liver cancer, pancreatitis, HIV, tuberculosis, and multiorgan failure. So the workflow is to culture blood, urine, and ascitic fluid and image the chest before starting, then a one-to-three-day observation window to stabilize and exclude occult infection, which is why the median time from admission to steroids in the trial was several days, reflecting how much screening the protocol requires.

6:29The Lille model is the response score that determines whether to continue or stop, calculated at day seven from age, albumin, prothrombin time, bilirubin, creatinine, and the change in bilirubin over that week, with a score under about half identifying responders who complete the full course with substantially improved survival, and a score at or above that threshold identifying nonresponders. The critical move on nonresponse is to stop the steroids, because continuing past day seven in a nonresponder doesn't improve survival but keeps adding infection risk, so the day-seven decision is binary in its consequence: responders continue, nonresponders stop and get evaluated for early transplant. N-acetylcysteine has supportive evidence as an adjunct, lowering one-month mortality partly through fewer hepatorenal and infectious events, so it's a reasonable add-on in patients who can receive steroids, while pentoxifylline is no longer recommended and other agents are in trials. Nutrition is consistently mortality-modifying and non-negotiable, with a target of thirty to forty kilocalories per kilogram a day and one and a half grams of protein per kilogram, by mouth or nasogastric tube, because very low voluntary intake predicts near-complete mortality while adequate intake cuts it substantially, and parenteral nutrition is avoided because of infection risk, with thiamine repletion, withdrawal management, electrolyte correction, and continuous infection surveillance completing the package.

7:54That brings the patient who fails medical therapy, whose six-month mortality without further intervention is high, most dying within six months. The historical answer was that transplant required six months of demonstrated sobriety first, but that rule was a center policy, never validated as a predictor of post-transplant abstinence, and it effectively excluded severe alcoholic hepatitis because most patients died within six months. A landmark study then tested early transplant in highly selected steroid nonresponders and found markedly improved six-month survival with a low recidivism rate in line with abstinence after the conventional rule, and a subsequent multicenter experience confirmed one- and three-year survival comparable to transplant for other indications with a minority relapsing, whose predictors were younger age, prior alcohol-related consequences, and inadequate insight. So the field has retired the six-month rule in favor of a structured psychosocial assessment that selects the patients most likely to maintain abstinence regardless of disease timing, centered on a multidisciplinary review including addiction medicine, hepatology, transplant surgery, social work, and psychiatry, with the widely used scoring tools rating readiness, support, stability, and substance-use effects.

9:07The favorable selection criteria are concrete: this must be the first liver-decompensating event, the patient must have failed or be ineligible for medical therapy, which usually means a day-seven Lille above the threshold or a steroid contraindication at the outset, there must be a supportive social network with close supports actively engaged, no more than one prior treatment attempt should have failed, there must be no other active substance use disorder and no untreated severe psychiatric disease, and the patient must demonstrate insight and commit with the family to lifelong sobriety. So the favored vignette is a first-decompensation patient started on prednisolone whose day-seven Lille is above the threshold with a still-rising bilirubin, who has strong family support, no prior treatment failure, and clear insight, where the action is referral for early-transplant evaluation, not continued steroids past day seven, not adding N-acetylcysteine, and not transitioning to comfort care, because the data say transplant and the patient meets the criteria. Post-transplant management has its own pharmacology, with acamprosate and baclofen preferred for alcohol use disorder in significant liver disease because acamprosate isn't hepatically metabolized and baclofen has been studied directly in cirrhotics, while disulfiram and oral naltrexone are used cautiously, with addiction support continuing indefinitely, and alcohol-associated liver disease is now the leading indication for liver transplant in the US.

10:29So the way of thinking runs along a single continuum: alcohol injury moves from steatosis through steatohepatitis to cirrhosis on the same biology, with reversibility at the front end and decompensation risk at the back. The acute superimposed syndrome of severe alcoholic hepatitis is identified by a Maddrey above thirty-two or a MELD over twenty, treated with prednisolone only after infection is screened, with the day-seven Lille as the response decision, and nonresponders stopping steroids and being evaluated for early transplant, which is now established as a survival-saving option for highly selected patients with first decompensation, social support, and insight, because the six-month sobriety rule is no longer the criterion, the psychosocial assessment is.

11:13The next chapter moves to the inherited liver diseases: hereditary hemochromatosis with its gene and phlebotomy to a ferritin target, Wilson disease with the Leipzig score and the chelator-plus-zinc treatment, and the rest of the inherited disorders, including alpha-one antitrypsin, cystic fibrosis liver disease, polycystic liver disease, and the pediatric cholestasis spectrum.

11:33For the full chapter, the practice vignettes, and the topic-tagged question bank, head to board pearls dot com. You'll find the rest of the series on Apple Podcasts, Spotify, or wherever you listen to podcasts. That brings us to the end of episode two of two of chapter twenty-one, and I'll see you in the next one.